JP2022166006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022166006A5 JP2022166006A5 JP2022117520A JP2022117520A JP2022166006A5 JP 2022166006 A5 JP2022166006 A5 JP 2022166006A5 JP 2022117520 A JP2022117520 A JP 2022117520A JP 2022117520 A JP2022117520 A JP 2022117520A JP 2022166006 A5 JP2022166006 A5 JP 2022166006A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- tocilizumab
- composition according
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196625 | 2016-10-31 | ||
| EP16196625.4 | 2016-10-31 | ||
| PCT/EP2017/077793 WO2018078162A1 (en) | 2016-10-31 | 2017-10-30 | Liquid pharmaceutical composition |
| JP2019522329A JP2019536761A (ja) | 2016-10-31 | 2017-10-30 | 液体医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522329A Division JP2019536761A (ja) | 2016-10-31 | 2017-10-30 | 液体医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022166006A JP2022166006A (ja) | 2022-11-01 |
| JP2022166006A5 true JP2022166006A5 (enExample) | 2022-12-08 |
| JP7473603B2 JP7473603B2 (ja) | 2024-04-23 |
Family
ID=57218780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522329A Pending JP2019536761A (ja) | 2016-10-31 | 2017-10-30 | 液体医薬組成物 |
| JP2022117520A Active JP7473603B2 (ja) | 2016-10-31 | 2022-07-22 | 液体医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522329A Pending JP2019536761A (ja) | 2016-10-31 | 2017-10-30 | 液体医薬組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11291725B2 (enExample) |
| EP (2) | EP3532029B1 (enExample) |
| JP (2) | JP2019536761A (enExample) |
| KR (1) | KR20190078572A (enExample) |
| CN (1) | CN110062620B (enExample) |
| AU (1) | AU2017351805A1 (enExample) |
| BR (1) | BR112019006853B1 (enExample) |
| CA (1) | CA3040342A1 (enExample) |
| DK (1) | DK3532029T3 (enExample) |
| ES (1) | ES2882181T3 (enExample) |
| HU (1) | HUE054858T2 (enExample) |
| MY (1) | MY192532A (enExample) |
| RU (1) | RU2019116756A (enExample) |
| SG (1) | SG11201902531QA (enExample) |
| WO (1) | WO2018078162A1 (enExample) |
| ZA (1) | ZA201901736B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN110062620B (zh) * | 2016-10-31 | 2023-12-05 | 德国费森尤斯卡比有限公司 | 液体药物组合物 |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US12433948B2 (en) * | 2018-10-31 | 2025-10-07 | Richter Gedeon Nyrt | Aqueous pharmaceutical formulations |
| WO2021119330A1 (en) * | 2019-12-10 | 2021-06-17 | Maxim Skulachev | Polymer matrixes for different compositions of mitochondrially targeted antioxidants |
| EP4117727A2 (en) * | 2020-03-10 | 2023-01-18 | Tiziana Life Sciences PLC | Compositions of il-6/il-6r antibodies and methods of use thereof |
| ES2987347T3 (es) * | 2020-03-13 | 2024-11-14 | Lek Pharmaceuticals | Estabilización de composiciones farmacéuticas que comprenden polisorbato |
| WO2022006051A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Formulation of tocilizumab and method for treating covid-19 by inhalation |
| KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| US20230090654A1 (en) * | 2021-08-24 | 2023-03-23 | Homology Medicines, Inc. | Adeno-associated virus formulations |
| WO2024043837A1 (en) * | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
| KR102554775B1 (ko) | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| WO2024257040A1 (en) * | 2023-06-14 | 2024-12-19 | Enzene Biosciences Limited | Composition and stable liquid formulations comprising humanized anti-human interleukin 6 (il-6) receptor monoclonal antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW205553B (enExample) | 1991-04-25 | 1993-05-11 | Chugai Pharmaceutical Co Ltd | |
| DK1314437T3 (da) | 2000-08-11 | 2014-07-14 | Chugai Pharmaceutical Co Ltd | Stabiliserede antistofindeholdende præparater |
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| JP2009034095A (ja) * | 2007-07-06 | 2009-02-19 | Sanyo Chem Ind Ltd | タンパク質含有水溶液安定化剤、タンパク質含有水溶液の安定化方法及びタンパク質含有水溶液 |
| KR20100044261A (ko) * | 2007-08-27 | 2010-04-29 | 바이오제너릭스 에이지 | Ｇ-ｃｓｆ의 액상 조성물 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| KR20220070586A (ko) * | 2010-11-08 | 2022-05-31 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| US20150150979A1 (en) * | 2012-06-21 | 2015-06-04 | Ucb Pharma, S.A. | Pharmaceutical formulation |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
| CN110062620B (zh) * | 2016-10-31 | 2023-12-05 | 德国费森尤斯卡比有限公司 | 液体药物组合物 |
-
2017
- 2017-10-30 CN CN201780067178.XA patent/CN110062620B/zh active Active
- 2017-10-30 JP JP2019522329A patent/JP2019536761A/ja active Pending
- 2017-10-30 BR BR112019006853-8A patent/BR112019006853B1/pt active IP Right Grant
- 2017-10-30 MY MYPI2019001479A patent/MY192532A/en unknown
- 2017-10-30 KR KR1020197011677A patent/KR20190078572A/ko not_active Ceased
- 2017-10-30 US US16/346,215 patent/US11291725B2/en active Active
- 2017-10-30 WO PCT/EP2017/077793 patent/WO2018078162A1/en not_active Ceased
- 2017-10-30 RU RU2019116756A patent/RU2019116756A/ru unknown
- 2017-10-30 AU AU2017351805A patent/AU2017351805A1/en not_active Abandoned
- 2017-10-30 EP EP17797579.4A patent/EP3532029B1/en active Active
- 2017-10-30 EP EP21164822.5A patent/EP3964197A1/en active Pending
- 2017-10-30 CA CA3040342A patent/CA3040342A1/en active Pending
- 2017-10-30 ES ES17797579T patent/ES2882181T3/es active Active
- 2017-10-30 DK DK17797579.4T patent/DK3532029T3/da active
- 2017-10-30 SG SG11201902531QA patent/SG11201902531QA/en unknown
- 2017-10-30 HU HUE17797579A patent/HUE054858T2/hu unknown
-
2019
- 2019-03-20 ZA ZA201901736A patent/ZA201901736B/en unknown
-
2022
- 2022-02-24 US US17/680,155 patent/US20220175924A1/en active Pending
- 2022-07-22 JP JP2022117520A patent/JP7473603B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022166006A5 (enExample) | ||
| JP2019536761A5 (enExample) | ||
| JP2019534863A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| ES2540204T3 (es) | Formulaciones farmacéuticas de inhibidores de la HDAC | |
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| JP2020138981A5 (enExample) | ||
| JP2021155453A5 (enExample) | ||
| JP2024001364A5 (enExample) | ||
| JP2010513522A5 (enExample) | ||
| HRP20211417T1 (hr) | Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka | |
| JP2013521296A5 (enExample) | ||
| JP2008526757A5 (enExample) | ||
| JP2020183387A5 (enExample) | ||
| JP2012526121A5 (enExample) | ||
| JP2018021007A5 (enExample) | ||
| RU2007142454A (ru) | Композиции, содержащие пиперациллин и тазобактам, применимые для инъекции | |
| JP2019504086A5 (enExample) | ||
| JP2015535237A5 (enExample) | ||
| CA2672902A1 (en) | Formulations | |
| JP2011502968A5 (enExample) | ||
| HRP20241526T1 (hr) | Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans | |
| CL2017002488A1 (es) | Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012) | |
| CN102985069B (zh) | 稳定的随时可用的对乙酰氨基酚注射制剂 | |
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc |